The data presented at CROI 2022 had particular relevance for the Central and Eastern European regions, where there are significant delays in PrEP for HIV, varied approaches to HIV/HCV coinfection, and a high prevalence of TB.
Self-administered long-acting antiretroviral therapy will empower people with HIV and enhance patient privacy, but there may be trade-offs.
My perspective on how the latest data on long-acting antiretrovirals presented at CROI 2022 will impact HIV prevention and management in Africa.
Read my thoughts on the most important papers on HIV cure from the recent CROI 2022 virtual meeting.
Read my take on promising new data from CROI 2022 on a vaginal ring containing tenofovir and long-acting cabotegravir as PrEP.
Here’s my take on the latest data from the VISEND and 2SD studies presented at CROI 2022.
Read my thoughts on new data from the recent CROI 2022 virtual meeting in support of using dolutegravir in second-line HIV therapy.
Découvrez les résumés d’études clés sur le VIH présentés par des professeurs experts lors de la CROI 2022, notamment les résultats d’études sur les stratégies de prévention, les thérapies à action prolongée, les traitements de deuxième intention, les comorbidités et le remède.
Leia os resumos dos principais estudos de VIH dos membros do corpo docente especialistas do CROI 2022, incluindo resultados de estudos de estratégias de prevenção, terapias de ação prolongada, terapias de segunda linha, comorbidades e cura.
Lea los resúmenes de un panel de expertos de los estudios clave sobre el VIH de CROI 2022, incluidos los resultados de los estudios de estrategias de prevención, terapias de acción prolongada, tratamientos de segunda línea, comorbilidades y cura.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.